ExPLoRNA Therapeutics receives funding to advance its novel mRNA technology
ExPLoRNA Therapeutics, a Polish biotech company revolutionizing mRNA vaccines and therapeutics with unprecedented translational efficiency, received funding from the Bill & Melinda Gates Foundation to further develop its unique mRNA technology. ExPLoRNA specializes in novel cap analogs, the starting part of mRNA that is crucial for enabling successful production of the encoded protein. ExPLoRNA's technology increases protein production beyond scale observable so far with other standard cap analogs.

Symbolic image
Computer-generated image
Total funding received from the Bill & Melinda Gates Foundation is $813,578 and will be used for a 14-month project. The project aims to better understand the benefits of ExPLoRNA's cap analogs, especially in terms of reducing the mRNA dose needed for therapeutic effects in the settings of vaccination and monoclonal antibody production.
The planned experiments include the use of the state-of-the-art, clinically validated lipid nanoparticle (LNP) formulations from Acuitas Therapeutics. Acuitas is known for its successful role in providing the LNP technology for one of the only two regulatory-approved mRNA-based COVID-19 vaccines.
ExPLoRNA Therapeutics is the first Polish biotech company to receive funding from Bill & Melinda Gates Foundation. Through this project, ExPLoRNA Therapeutics commits to its vision of making mRNA technology more accessible in low-income countries to help fight disesaes threatening human lives and well-being.
"We are grateful for the foundation's support to help us achieve our vision. With the help of this grant, we intend to speed up the development of future mRNA vaccines and therapies." – comments Jacek Jemielity, CEO of ExPLoRNA Therapeutics, and professor at the University of Warsaw.
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.